Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
New car owner analysis from Insurify finds drivers spend an average of $5,851 a year on insurance, gas and maintenance alone, separate from financing costs.
Oil prices are climbing again after Saudi Arabia shut down a critical pipeline that has served as a major alternative route around the Strait of Hormuz.
Ryan Hamburger, Chief Commercial Officer at Instacart, explains how Clementine uses AI to personalize grocery shopping, build carts, find deals, and save time.
Ari Hawkins, Trade Reporter at POLITICO, examines Canada’s retaliation, Trump’s latest trade threats and the potential impact on businesses and consumers.
